The White House abruptly withdrew Dr. Heidi Overton's nomination to lead the Food and Drug Administration late Tuesday, ending her bid to run the agency just hours before a Senate committee was scheduled to vote on whether to advance her to the full Senate. The decision, first reported by Axios and confirmed by a White House official, leaves the FDA without a permanent commissioner — a vacancy that now looks likely to stretch well into next year.
![]() |
| Dr. Heidi Overton, the White House aide nominated in August to lead the Food and Drug Administration. |
A Nomination Pulled at the Last Moment
The White House moved on Tuesday night, November 17, to pull Overton's nomination, one day before the Senate Health, Education, Labor and Pensions (HELP) Committee was due to vote on it. The committee had been scheduled to vote at 10 a.m. on Wednesday, November 18, on whether to send her nomination to the full Senate.
According to a senior administration official who spoke to Axios, Overton "lacks the support on the Hill to move forward with her confirmation." A White House official confirmed the withdrawal to USA Today and other outlets, but the White House did not immediately explain its decision in public or give a timeline for choosing a new nominee.
The timing stunned even the committee's own chairman. Senator Bill Cassidy, the Louisiana Republican who chairs the HELP Committee, wrote on X shortly after the news broke: "Tonight, the White House abandoned a viable confirmation path for Dr. Overton." Cassidy maintained that she had been on the verge of gathering enough support to advance, and argued that the administration withdrew her rather than give anti-abortion Republicans the assurances they were seeking about the abortion pill mifepristone.
The Senate Math That Doomed the Pick
Overton's problem was arithmetic. The HELP Committee has 21 members, and Republicans hold only a one-vote majority on the panel. With every Democrat expected to oppose her, Overton needed unanimous Republican support to advance to the full Senate — meaning a single Republican defection would have sunk her nomination.
That support was never secured. In the hours before the withdrawal, Senators Susan Collins of Maine and Lisa Murkowski of Alaska — the two Republicans most often watched in close confirmation fights — had not said how they would vote, according to CBS News. Other Republicans had voiced doubts for weeks, and the White House ultimately decided not to risk a public defeat in committee.
The withdrawal followed weeks of intensifying scrutiny of Overton from both Republican senators and activists aligned with Health and Human Services Secretary Robert F. Kennedy Jr., according to CNN, which described her relationship with Kennedy as "icy."
Who Heidi Overton Is
Overton is a preventive medicine physician who holds both a medical degree and a doctorate. At the time of her nomination, she served as deputy director of the White House Domestic Policy Council, a senior policy role inside the administration. Before joining the White House, she worked at the America First Policy Institute, a conservative think tank.
President Donald Trump nominated her on August 19 to replace Dr. Marty Makary, who resigned as FDA commissioner in May. The pick came three months after Makary's departure, and it immediately drew questions about whether a White House policy aide — rather than a veteran of the agency or a prominent figure in medicine — was the right choice to lead one of the federal government's most consequential health agencies.
The FDA regulates prescription drugs, vaccines, medical devices, and the nation's food supply, and its commissioner shapes decisions that touch nearly every American family. The agency has been without a Senate-confirmed leader since May, with Kyle Diamantas, the FDA's deputy commissioner for food, serving as acting commissioner in the interim.
A Rocky Confirmation Hearing
Overton's confirmation hearing before the HELP Committee in September set the tone for the months that followed. Senators pressed her on vaccines, abortion, and flavored vaping products, and on whether she believed President Trump was capable of being wrong — a line of questioning that drew wide attention at the time.
Even before the hearing, Cassidy had publicly aired doubts. He wrote on X that he had "strong concerns" about the nomination, saying Overton's lack of managerial experience left her poorly prepared to run an agency the size of the FDA.
The abortion pill mifepristone became a central flashpoint. Senators and anti-abortion activists pressed Overton on how the FDA would handle oversight of the drug, including proposed requirements for in-person ultrasounds and stricter reporting of adverse events, and questioned whether her positions were consistent with the administration's own litigation stances. The FDA is set to finish a safety review of mifepristone in March, one of the most consequential decisions the agency faces.
Flavored vaping products were another source of friction. Makary resigned in May in part because of the administration's decision to authorize several fruit-flavored vaping products, according to reports, and the issue continued to divide Republicans during Overton's confirmation process.
A Pattern of Pulled Health Nominees
Overton is not the first health nominee the White House has been forced to abandon. The administration has also yanked nominees to lead the Centers for Disease Control and Prevention and the surgeon general's office as moderate Republicans voiced concerns, according to CNN.
The pattern points to a recurring tension inside the administration's health agenda: nominees who satisfy one wing of the Republican coalition — whether on abortion, vaccines, or vaping — often draw objections from another, and the White House has repeatedly chosen withdrawal over a bruising confirmation fight.
For the FDA, the stakes of that pattern are unusually high. The agency has now spent more than six months without a permanent commissioner, and the withdrawal of Overton's nomination means the search starts over from scratch.
![]() |
| The Food and Drug Administration headquarters in White Oak, Maryland. The agency has been without a Senate-confirmed commissioner since May. |
What This Means
The collapse of Overton's nomination is, above all, a sign of how narrow the administration's margin has become in the Senate. A nominee who could not afford to lose a single Republican on a 21-member committee was always one defection away from failure, and the White House concluded — despite Cassidy's insistence that a path existed — that the votes were not there.
It also shows the limits of picking a loyal insider for a job that demands broad credibility. Overton's White House pedigree was her main qualification in the president's eyes, but it became a liability in the Senate, where members of both parties questioned her management experience and her independence from the administration she served.
The dispute over mifepristone, meanwhile, underlines how central abortion politics remain to the FDA's work. The agency's safety review of the drug, due in March, will land on the desk of whoever eventually leads the FDA — and the fight over Overton suggests that any future nominee will face the same questions, and the same pressure, on that issue.
![]() |
| The U.S. Capitol in Washington. Democrats are set to take control of the Senate in January, narrowing the window to confirm a new FDA chief. |
What Happens Next
The White House has not said when it will name a new nominee, and the calendar is now working against it. Democrats are set to take control of the Senate in January after winning majorities in both chambers in the midterm elections, which means the window for confirming a Republican-backed commissioner is closing fast. As Cassidy put it, confirming a permanent FDA commissioner will now fall to Senate Democrats.
One name already circulating is Senator Roger Marshall of Kansas, a former obstetrician who lost his reelection bid this month. According to Reuters, the White House is weighing Marshall as a replacement nominee, and Marshall has expressed interest in the role to the administration. Nothing has been decided, and the White House has not confirmed that he is under consideration.
In the meantime, Diamantas will continue to lead the FDA in an acting capacity, steering the agency through a crowded agenda that includes the mifepristone safety review, vaccine policy, drug approvals, and food safety. The question now is whether the White House can find a nominee who can satisfy its own coalition and win over a Senate that is about to change hands — or whether the FDA will begin 2027 the way it spent most of 2026: leaderless at the top.



Post a Comment